WO2022218238A1 - 中草药组合物及其食品、清洁剂、保养品及其用于制备冠状病毒治疗药及肠病毒治疗药的用途 - Google Patents

中草药组合物及其食品、清洁剂、保养品及其用于制备冠状病毒治疗药及肠病毒治疗药的用途 Download PDF

Info

Publication number
WO2022218238A1
WO2022218238A1 PCT/CN2022/086014 CN2022086014W WO2022218238A1 WO 2022218238 A1 WO2022218238 A1 WO 2022218238A1 CN 2022086014 W CN2022086014 W CN 2022086014W WO 2022218238 A1 WO2022218238 A1 WO 2022218238A1
Authority
WO
WIPO (PCT)
Prior art keywords
medicinal material
chinese herbal
medicine composition
herbal medicine
cleaning agent
Prior art date
Application number
PCT/CN2022/086014
Other languages
English (en)
French (fr)
Inventor
朱修信
Original Assignee
京曜生医股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 京曜生医股份有限公司 filed Critical 京曜生医股份有限公司
Publication of WO2022218238A1 publication Critical patent/WO2022218238A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254—Acanthopanax or Eleutherococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/533—Leonurus (motherwort)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/634—Forsythia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718—Coptis (goldthread)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction

Definitions

  • the invention relates to a Chinese herbal medicine composition, in particular to the use of a Chinese herbal medicine composition for preparing a coronavirus therapeutic drug.
  • SARS-CoV-2 coronavirus
  • COVID-19 coronavirus
  • the new coronavirus has the characteristics of high-speed mutation.
  • medicine has not yet grasped the whole picture, and it is difficult to develop a vaccine that can be effective for a long time.
  • An effective vaccine may also be less effective or even lose its effect due to the mutation of the virus.
  • chemically synthesized drugs are currently used, including RNA synthesis inhibitors or protease inhibitors.
  • such drugs may also inhibit the proliferation of normal cells while preventing virus replication, resulting in serious side effects.
  • the materials of the existing traditional Chinese medicine are derived from natural plants, which have less side effects on the human body, and are suitable for diseases that cause serious damage to the human body and may still produce various sequelae after treatment. It is expected that the quality of life after treatment will improve promote.
  • the purpose of the present invention is to provide a Chinese herbal medicine composition, which can effectively inhibit the infection of the novel coronavirus, has low toxicity to the human body, and is less likely to produce side effects.
  • the present invention provides a Chinese herbal medicine composition by technical means used to solve the problems of the prior art, comprising: the first medicinal material is licorice; the second medicinal material is mint; the third medicinal material is Pu'er; and the fourth medicinal material is At least one medicinal material is selected from the medicinal material group consisting of ginger, ginseng, coptis, angelica, rehmannia glutinosa, forsythia, wolfberry, tuckahoe, wujia and motherwort, wherein the first medicinal material, the second medicinal material, the third medicinal material
  • the Chinese herbal medicine composition is prepared by mixing the medicinal material and the fourth medicinal material and boiling with water.
  • An embodiment of the present invention provides a Chinese herbal medicine composition, wherein in the Chinese herbal medicine composition, the content of the first medicinal material is 1 to 50 wt %, the content of the second medicinal material is 1 to 50 wt %, and the content of the third medicinal material is 1 to 50 wt %.
  • the content of the medicinal material is 1 to 80 wt %, the content of the fourth medicinal material is 1 to 15 wt %, and the sum of the contents of the first medicinal material, the second medicinal material, the third medicinal material and the fourth medicinal material is 100 wt %.
  • a food which contains the aforementioned Chinese herbal medicine composition.
  • the aforementioned food is provided, wherein the food is a beverage.
  • the aforementioned food is provided, wherein the food is packaged in capsules.
  • a cleaning agent which contains the aforementioned Chinese herbal medicine composition.
  • the aforementioned cleaning agent is provided, wherein the cleaning agent is a spray.
  • the aforementioned cleaning agent is provided, wherein the cleaning agent is dry hand.
  • the aforementioned cleaning agent is provided, wherein the cleaning agent is a cleaning agent.
  • a skin care product which comprises the aforementioned Chinese herbal medicine composition.
  • the aforementioned skin care product is provided, wherein the skin care product is a skin care solution.
  • the aforementioned skin care product is provided, wherein the skin care product is a cream.
  • the aforementioned skin care product is provided, wherein the skin care product is a spray.
  • the Chinese herbal medicine composition of the present invention can be used for the preparation of coronavirus therapeutic drugs and enterovirus therapeutic drugs, so as to be able to effectively inhibit the infection of novel coronaviruses and enteroviruses, and be less likely to cause side effects on the human body, and can be included in food, cleaning It has antiviral effect in medicines and skin care products.
  • FIG. 1 is a graph showing the results of animal experiments of the Chinese herbal medicine composition according to the first embodiment of the present invention.
  • FIG. 2 is a graph showing the analysis scale of the animal experiment results of the Chinese herbal medicine composition according to the first embodiment of the present invention.
  • SARS-CoV-2 pseudovirus used in the experiments described below is a pseudovirus system established for SARS-CoV-2 (ie, COVID-19) for research and experimental use.
  • the basic infectious properties of SARS-CoV-2 pseudovirus are the same as SARS-CoV-2, which means that the results obtained from experiments using SARS-CoV-2 pseudovirus should also be applicable to SARS-CoV-2.
  • the first medicinal material is licorice
  • the second medicinal material is mint
  • the third medicinal material is Pu'er
  • At least one fourth medicinal material selected from the medicinal material group consisting of Wujia, Wujia and Motherwort is prepared by mixing and boiling with water.
  • the content of the first medicinal material is 1 to 50 wt %
  • the content of the second medicinal material is 1 to 50 wt %
  • the content of the third medicinal material is 1 to 80 wt %
  • the content of the fourth medicinal material 1 to 15 wt %
  • the sum of the contents of the first medicinal material, the second medicinal material, the third medicinal material and the fourth medicinal material is 100 wt %.
  • the Chinese herbal medicine composition is hereinafter referred to as CV19-XH.
  • HepG2 cells were cultured in DMEM medium, the Chinese herbal medicine composition prepared by boiling was diluted into different concentrations (unit: weight percent) with deionized water, and then added to the culture medium of the cells for processing. After 24 hours of drugs After processing, use commercially available One Solution Assay Kit to analyze cell viability. The analysis results are shown in Table 1.
  • the cause of the side effects is that when the components of the drug exert their effects, they will also affect normal human cells, causing the death of normal human cells and causing harm to the human body.
  • the Chinese herbal medicine composition of the present invention has no toxicity to human cells and will not cause abnormal death of human cells. Therefore, it is expected that the Chinese herbal medicine composition of the present invention will not cause serious side effects when taken.
  • IC50 half maximal inhibitory concentration
  • HepG2 cells were cultured in DMEM medium and infected with SARS-CoV-2 pseudovirus, the Chinese herbal medicine composition prepared by boiling was diluted with deionized water to different concentrations (unit: weight percentage) and added to the medium of the cells After 24 hours of drug treatment, use commercially available Luciferase Assay system to analyze the fluorescence intensity of virions. The analysis results are shown in Table 2.
  • the Chinese herbal medicine composition according to the present invention indeed has the effect of inhibiting coronavirus infection, and can be used as a drug against coronavirus infection.
  • the concentration in the test concentration range the higher the inhibition rate, so the expected effect can be obtained at a lower concentration in actual use, which further reduces the possibility of side effects.
  • mice of the Balb/c strain using commercially available Luciferase Assay system, only normal saline was administered to the control group, the infection group was only infected with SARS-CoV-2 pseudovirus, and the CV19-XH high-dose group was administered 5% CV19-XH after infection with SARS-CoV-2 pseudovirus, The CV19-XH low-dose group was administered 1% CV19-XH after SARS-CoV-2 pseudovirus infection, and 24 hours after administration, the fluorescence in the mice was photographed with IVIS Spectrum and the fluorescence intensity was calculated. The results are shown in Figure 1 and figure 2.
  • Vero cells were cultured in DMEM medium and infected with Enterovirus 71.
  • the Chinese herbal medicine composition prepared by boiling was diluted with deionized water to different concentrations (unit: weight percent) and added to the cell culture medium for treatment.
  • the amount of viral RNA was analyzed by RT-qPCR and displayed as a comparison value when the infected and untreated group was 100%. The analysis results are shown in Table 4.
  • Vero cells are relatively sensitive to CV19-XH, but even at a concentration of 0.16%, which has little effect on cell activity, CV19-XH can inhibit the amount of EV71 RNA by more than 80%.
  • the inhibitory effect showed that CV19-XH can exert an inhibitory effect on enterovirus infection.
  • the Chinese herbal medicine composition of the present invention can be added to a food for use, and the food can be made into a beverage or a capsule package.
  • the Chinese herbal medicine composition of the present invention can be added to a cleaning agent for use, and the cleaning agent can be made into the form of a spray, a hand-drying agent or a cleaning agent.
  • the Chinese herbal medicine composition of the present invention can be added to a skin care product for use, and the skin care product can be prepared in the form of a sample preservation solution, a cream or a spray.
  • the Chinese herbal medicine composition of the present invention has no significant toxicity to the human body, and can inhibit the infection of novel coronavirus and enterovirus, and is suitable as a good therapeutic drug for coronavirus infection or enterovirus infection, And the side effects are minimal to none.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Virology (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

一种中草药组合物，包含第一药材甘草，第二药材薄荷，第三药材普洱，以及第四药材，为自生姜、人参、黄连、白芷、地黄、连翘、枸杞、土茯苓、五加皮及益母草所构成的药材群组中选择出至少一个药材，包含于食品、清洁剂及保养品中，制备冠状病毒治疗药及肠病毒治疗药。

Description

中草药组合物及其食品、清洁剂、保养品及其用于制备冠状病毒治疗药及肠病毒治疗药的用途
相关申请的交叉引用
本申请主张2021年4月16日提交的申请号为202110393747.8的中国发明专利申请的优先权，其内容通过引用的方式并入本申请中。
技术领域
本发明涉及一种中草药组合物，特别是涉及一种中草药组合物用于制备冠状病毒治疗药的用途。
背景技术
目前，新型冠状病毒(SARS-CoV-2，即COVID-19)的感染，对全世界造成巨大影响，此一新型的病毒传染力强，具有多样的传染途径，并且染疫之后发展为重症的速度快，即使痊愈亦可能留下诸多后遗症，成为社会的极大隐忧，迫使人们的生活型态改变，经济亦备受冲击。
同时新型冠状病毒具有高速突变的特性，目前医学尚未能掌握其全貌，难以开发出能够长时间有效的疫苗，而有效的疫苗亦可能会因为病毒的突变而效果降低，甚至失去效果。至于对于新型冠状病毒的治疗，目前多采用化学合成的药物，包括RNA合成抑制剂或是蛋白酶抑制剂。但是此类药物在阻止病毒复制的同时亦有可能会抑制正常细胞的增生，而产生严重的副作用。
另一方面，现有中药的材料源自于天然植物，对人体产生的副作用较小，适用于对人体的损害严重，愈后仍可能产生多种后遗症的疾病，可期待治疗后的生活质量的提升。
发明内容
因此，本发明的目的即在提供一种中草药组合物，能够有效抑制新型冠状病毒的感染，并且对人体的毒性低，不易产生副作用。
本发明为解决现有技术的问题所采用的技术手段提供一种中草药组合物，包含：第一药材，为甘草；第二药材，为薄荷；第三药材，为普洱；以及第四药材，为自生姜、人参、黄连、白芷、地黄、连翘、枸杞、土茯苓、五加及益母草所构成的药材群组中选择出至少一个 药材，其中该第一药材、该第二药材、该第三药材及该第四药材经混合并加水熬煮而制成该中草药组成物。
在本发明的一实施例中提供一种中草药组合物，其中在该中草药组合物中，该第一药材的含量为1至50wt％，该第二药材的含量为1至50wt％，该第三药材的含量为1至80wt％，该第四药材的含量为1至15wt％，且该第一药材、该第二药材、该第三药材及该第四药材的含量的总和为100％wt。
在本发明的一实施例中提供一种食品，其中包含有如前述的中草药组合物。
在本发明的一实施例中提供如前述的食品，其中该食品为饮品。
在本发明的一实施例中提供如前述的食品，其中该食品为胶囊包装。
在本发明的一实施例中提供一种清洁剂，其中包含有如前述的中草药组合物。
在本发明的一实施例中提供如前述的清洁剂，其中该清洁剂为喷剂。
在本发明的一实施例中提供如前述的清洁剂，其中该清洁剂为干洗手。
在本发明的一实施例中提供如前述的清洁剂，其中该清洁剂为洗洁剂。
在本发明的一实施例中提供一种保养品，其中包含有如前述的中草药组合物。
在本发明的一实施例中提供如前述的保养品，其中该保养品为保养液。
在本发明的一实施例中提供如前述的保养品，其中该保养品为乳膏。
在本发明的一实施例中提供如前述的保养品，其中该保养品为喷雾。
在本发明的一实施例中提供一种如前述的中草药组合物用于制备冠状病毒感染治疗药的用途。
在本发明的一实施例中提供一种如前述的中草药组合物用于制备肠病毒感染治疗药的用途。
根据本发明的中草药组合物，能够用于制备冠状病毒治疗药及肠病毒治疗药，以能够有效抑制新型冠状病毒及肠病毒的感染，并且不易产生对人体的副作用，并能够包含于食品、清洁剂及保养品中，发挥抗病毒的效果。
附图说明
图1为显示根据本发明的第一实施例的中草药组合物的动物实验结果图。
图2为显示根据本发明的第一实施例的中草药组合物的动物实验结果分析量表图。
具体实施方式
以下根据图表而说明本发明的实施方式。该说明并非为限制本发明的实施方式，而为本发明的实施例的一种。
以下所述实验中所使用的SARS-CoV-2 pseudovirus为建立为供研究及实验所使用的SARS-CoV-2(即COVID-19)的假病毒系统。SARS-CoV-2 pseudovirus的基本感染特性与SARS-CoV-2相同，也就是说使用SARS-CoV-2 pseudovirus进行实验所得的结果应亦能够应用于SARS-CoV-2。
依据本发明的一实施例的中草药组合物，将第一药材的甘草，第二药材的薄荷，第三药材的普洱，及自生姜、人参、黄连、白芷、地黄、连翘、枸杞、土茯苓、五加及益母草所构成的药材群组中选择出至少一种的第四药材经混合并加水熬煮而制成。
其中在该中草药组合物中，该第一药材的含量为1至50wt％，该第二药材的含量为1至50wt％，该第三药材的含量为1至80wt％，该第四药材的含量为1至15wt％，且该第一药材、该第二药材、该第三药材及该第四药材的含量的总和为100％wt。
接着以如前述方法制成的该中草药组合物进行细胞毒性实验。以下将该中草药组合物称为CV19-XH。
将HepG2细胞培养于DMEM培养基中，将熬煮制成的该中草药组合物经去离子水稀释为不同浓度(单位：重量百分比)后加入该细胞的培养基中进行处理，经过24小时的药物处理后，使用市售的
Figure PCTCN2022086014-appb-000001
One Solution Assay套件以分析细胞存活率。分析结果如表1所示。
表1
Figure PCTCN2022086014-appb-000002
如表1所示，自实验的结果能够得知HepG2细胞经过CV19-XH处理后，存活率相较于未加入药物的控制组，存活率并未显著降低，由此结果可以确定CV19-XH对于细胞并不具有毒性。
副作用的成因，便是作为药物的成份在发挥效果时，同时也会对正常的人体细胞产生影 响，造成正常的人体细胞的死亡而对人体造成伤害。本发明的中草药组合物通过上述的实验证实其对于人体细胞并没有毒性，不会造成人体细胞异常死亡，因此可期待本发明的中草药组合物在服用时不会带来严重的副作用。
进一步，进行以CV19-XH处理经SARS-CoV-2 pseudovirus感染的细胞的半最大抑制浓度((half maximal inhibitory concentration,IC50)的测试。
将HepG2细胞培养于DMEM培养基中并以SARS-CoV-2 pseudovirus感染，将熬煮制成的该中草药组合物经去离子水稀释为不同浓度(单位：重量百分比)后加入该细胞的培养基中进行处理，经过24小时的药物处理后，使用市售的
Figure PCTCN2022086014-appb-000003
Luciferase Assay系统以分析病毒体的荧光强度。分析结果如表2所示。
表2
Figure PCTCN2022086014-appb-000004
如表2所示，经过CV19-XH处理后的组别，其所表现出的荧光强度显著降低，且其抑制率与CV19-XH的浓度有明确的正相关性，也就是说CV19-XH对于SARS-CoV-2 pseudovirus的总量显著降低，并且其IC50的值落于CV19-XH的浓度为1.4％时。
由结果可知，依据本发明的中草药组合物，确实具有能够抑制冠状病毒感染的效果，而能够作为抗冠状病毒感染的药剂使用。同时，由表2的数据可得知，在测试浓度范围内浓度越低，抑制率越高，因此在实际使用时能够以较低的浓度得到预期的效果，进一步降低产生副作用的可能性。
进一步，进行将CV19-XH投予至经过SARS-CoV-2 pseudovirus感染的老鼠体内的动物实验，投予方式为将通过如前所述的稀释方式制成的不同浓度(单位：重量百分比)的CV19-XH溶液以喷雾状令老鼠吸入。
使用动物为Balb/c品系的老鼠，使用市售的
Figure PCTCN2022086014-appb-000005
Luciferase Assay系统，对控制组仅投予生理食盐水，感染组仅经过SARS-CoV-2 pseudovirus感染，CV19-XH高剂量组在经过SARS-CoV-2 pseudovirus感染后投予5％CV19-XH，CV19-XH低剂量组在经过SARS-CoV-2  pseudovirus感染后投予1％CV19-XH，并在投药24小时后，以IVIS Spectrum拍摄老鼠体内的荧光并计算荧光强度，结果显示于图1及图2。
如图1所示，老鼠经过CV19-XH处理后，与感染组相比可以发现荧光强度明显降低，也就是说对感染SARS-CoV-2 pseudovirus的老鼠投予CV19-XH，能够显著地减少老鼠体内SARS-CoV-2 pseudovirus的量。
又，进行了以CV19-XH处理经Enterovirus 71感染的细胞的半最大有效浓度((half maximal effective concentration,EC50)的测试。
首先进行细胞毒性实验，将Vero细胞培养于DMEM培养基中，将熬煮制成的该中草药组合物经去离子水稀释为不同浓度(单位：重量百分比)后加入该细胞的培养基中进行处理，经过48小时的药物处理后，使用市售的
Figure PCTCN2022086014-appb-000006
One Solution Assay套件以分析细胞存活率。分析结果如表3所示。
接着将Vero细胞培养于DMEM培养基中并以Enterovirus 71感染，将熬煮制成的该中草药组合物经去离子水稀释为不同浓度(单位：重量百分比)后加入该细胞的培养基中进行处理，经过48小时的药物处理后，以RT-qPCR进行病毒RNA量的分析，将其显示为以经感染且未经药物处理的组别为100％时的比较值。分析结果如表4所示。
表3
Figure PCTCN2022086014-appb-000007
表4
Figure PCTCN2022086014-appb-000008
如表1及表2所示，Vero细胞对于CV19-XH相对敏感，但是即使是CV19-XH为在几乎 不对细胞活性产生影响的0.16％浓度下，亦能够对EV71的RNA量有80％以上的抑制效果，显示CV19-XH能够发挥抑制肠病毒感染的效果。
依照本发明的一实施例，能够将本发明的中草药组合物加入于食品中使用，该食品能够制成饮品或是胶囊包装的型式。
依照本发明的另一实施例，能够将本发明的中草药组合物加入于清洁剂中使用，该清洁剂能够制成喷剂、干洗手或洗洁剂的型式。
依照本发明的又一实施例，能够将本发明的中草药组合物加入于保养品中使用，该保养品能够制成保样液、乳膏或喷雾的型式。
综上所述，本发明的中草药组合物对于人体不具有显著的毒性，并能够抑制新型冠状病毒及肠病毒的感染，适合作为一种良好的冠状病毒感染治疗药或是肠病毒感染治疗药，并且副作用微小乃至于无。
以上的叙述以及说明仅为本发明的较佳实施例的说明，对于本领域技术人员当可依据以上权利要求书以及上述的说明而作其他的修改，只是这些修改仍应是为本发明的发明精神而在本发明的保护范围中。

Claims (17)

  1. 一种中草药组合物，其特征在于，包含：
    第一药材，为甘草；
    第二药材，为薄荷；以及
    第三药材，为普洱，
    其中所述的第一药材、所述的第二药材及所述的第三药材经混合并加水熬煮而制成所述的中草药组成物。
  2. 根据权利要求1所述的中草药组合物，其特征在于，进一步包含第四药材，为自生姜、人参、黄连、白芷、地黄、连翘、枸杞、土茯苓、五加及益母草所构成的药材群组中选择出至少一个药材，与所述的第一药材、所述的第二药材及所述的第三药材混合并加水熬煮而制成所述的中草药组成物。
  3. 根据权利要求1所述的中草药组合物，其特征在于，在所述的中草药组合物中，所述的第一药材的含量为1至50wt％，所述的第二药材的含量为1至50wt％，所述的第三药材的含量为1至80wt％且所述的第一药材、所述的第二药材及所述的第三药材的含量的总和为100％wt。
  4. 根据权利要求2所述的中草药组合物，其特征在于，在所述的中草药组合物中，所述的第一药材的含量为1至50wt％，所述的第二药材的含量为1至50wt％，所述的第三药材的含量为1至80wt％，所述的第四药材的含量为1至15wt％，且所述的第一药材、所述的第二药材、所述的第三药材及所述的第四药材的含量的总和为100％wt。
  5. 一种食品，其特征在于，包含有权利要求1至4中任一项所述的中草药组合物。
  6. 根据权利要求5所述的食品，其特征在于，所述的食品为饮品。
  7. 根据权利要求5所述的食品，其特征在于，所述的食品为胶囊包装。
  8. 一种清洁剂，其特征在于，包含有权利要求1至4中任一项所述的中草药组合物。
  9. 根据权利要求8所述的清洁剂，其特征在于，所述的清洁剂为喷剂。
  10. 根据权利要求8所述的清洁剂，其特征在于，所述的清洁剂为干洗手。
  11. 根据权利要求8所述的清洁剂，其特征在于，所述的清洁剂为洗洁剂。
  12. 一种保养品，其特征在于，包含有权利要求1至4中任一项所述的中草药组合物。
  13. 根据权利要求12所述的保养品，其特征在于，所述的保养品为保养液。
  14. 根据权利要求12所述的保养品，其特征在于，所述的保养品为乳膏。
  15. 根据权利要求12所述的保养品，其特征在于，所述的保养品为喷雾。
  16. 一种根据权利要求1至4中任一项所述的中草药组合物用于制备冠状病毒感染治疗药的用途。
  17. 一种根据权利要求1至4中任一项所述的中草药组合物用于制备肠病毒感染治疗药的用途。
PCT/CN2022/086014 2021-04-13 2022-04-11 中草药组合物及其食品、清洁剂、保养品及其用于制备冠状病毒治疗药及肠病毒治疗药的用途 WO2022218238A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110393747.8 2021-04-13
CN202110393747.8A CN115192686A (zh) 2021-04-13 2021-04-13 中草药组合物及其用于制备冠状病毒治疗药的用途

Publications (1)

Publication Number Publication Date
WO2022218238A1 true WO2022218238A1 (zh) 2022-10-20

Family

ID=83571467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/086014 WO2022218238A1 (zh) 2021-04-13 2022-04-11 中草药组合物及其食品、清洁剂、保养品及其用于制备冠状病毒治疗药及肠病毒治疗药的用途

Country Status (2)

Country Link
CN (1) CN115192686A (zh)
WO (1) WO2022218238A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200503740A (en) * 2003-07-21 2005-02-01 xin-yuan Hu Decoction for resisting SARS
CN104431039A (zh) * 2013-09-25 2015-03-25 王少明 薄荷甘草茶
CN108185058A (zh) * 2018-03-30 2018-06-22 俞成莲 一种减肥果养生茶
CN109480000A (zh) * 2019-01-19 2019-03-19 崔彩霞 一种普洱茶的拼配工艺
CN111297967A (zh) * 2020-04-21 2020-06-19 湖南赵华文药业股份有限公司 一种预防治疗新冠肺炎的中药制剂及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103262923B (zh) * 2012-04-25 2015-01-14 辽宁医学院 一种清凉普洱保健茶及其制备工艺

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200503740A (en) * 2003-07-21 2005-02-01 xin-yuan Hu Decoction for resisting SARS
CN104431039A (zh) * 2013-09-25 2015-03-25 王少明 薄荷甘草茶
CN108185058A (zh) * 2018-03-30 2018-06-22 俞成莲 一种减肥果养生茶
CN109480000A (zh) * 2019-01-19 2019-03-19 崔彩霞 一种普洱茶的拼配工艺
CN111297967A (zh) * 2020-04-21 2020-06-19 湖南赵华文药业股份有限公司 一种预防治疗新冠肺炎的中药制剂及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Tea and Health", 28 February 2011, WORLD BOOK PUBLISHING COMPANY, CN, ISBN: 978-7-5100-2663-8, article TU, YOUYING: "II. Anti-SARS Coronavirus", pages: 153 - 154, XP009540427 *
LIN YAN: "Research Progress on Antiviral Effect of Traditional Chinese Medicine and its Bioactive Constituents", STRAIT PHARMACEUTICAL JOURNAL, vol. 33, no. 3, 15 March 2021 (2021-03-15), pages 1 - 7, XP055977284 *

Also Published As

Publication number Publication date
CN115192686A (zh) 2022-10-18

Similar Documents

Publication Publication Date Title
JP6381755B2 (ja) 生薬等含有医薬組成物（参）
Badmaev et al. Protection of epithelial cells against influenza A virus by a plant derived biological response modifier Ledretan‐96
CN113440563B (zh) 一种复方鱼腥草喷雾剂及其制备方法和应用
CN106310236A (zh) 一种抗氧化sod口腔喷雾剂及其制备方法
KR20220156604A (ko) 중약 조성물의 코로나 바이러스 감염 치료 또는 예방 약물 제조에서의 응용
WO2022218238A1 (zh) 中草药组合物及其食品、清洁剂、保养品及其用于制备冠状病毒治疗药及肠病毒治疗药的用途
WO2010040254A1 (zh) 黄芩黄酮在制备治疗肠道病毒感染药物的应用
CN103768157A (zh) 一种兽用抗病毒中药紫芪泡腾颗粒药物及其制备方法
Borquaye et al. Anti-inflammatory, antioxidant and total phenolic content of the ethanolic extracts of Celtis africana Burm. f
TW202239425A (zh) 中草藥組合物用於製備冠狀病毒治療藥及腸病毒治療藥的用途
WO2022220767A1 (en) A pharmaceutical product for prophylaxis and treatment of viral diseases caused by coronavirus (sars-cov-2 or covid-19)
TWI359669B (zh)
Zulkapli et al. The preliminary cytotoxicity study: anti-proliferative activity of aqueous extract of Clinacanthus nutans, Strobilanther crispa and Pereskia bleo on oral squamous carcinoma cells ORL-48
CN104161902B (zh) 一种药物组合物及其制剂在制备抗流感药物中的新用途
Vilhelmova-Ilieva et al. Antiviral Potential of Specially Selected Bulgarian Propolis Ex-Tracts: In Vitro Mechanism of Action Against Structurally Differ-Ent Viruses
WO2021220297A1 (en) A novel polyherbal pharmaceutical composition exhibiting immunomodulatory and anti-viral activity and method of preparation thereof
CN111803418B (zh) 一种抗病毒组合物及其在儿童日用品中的应用
Mpongo et al. In vitro evaluation of the cytotoxicity of Dissotis rotundifolia (Sm.) Triana (Melastomataceae) and Emilia sagittata (Vahl) DC.(Asteraceae) plants used in intimate hygiene among women in Mbandaka, Democratic Republic of the Congo
CN106038686A (zh) 抗流感病毒含片及其制备方法
Khales et al. In Vitro Assessment of The Effects of Althaea Officinalis Root Extract on Rotavirus Multiplication
JP2023143801A (ja) 抗ライノウイルス剤
WO2021245696A1 (en) Herbal mouthwash formulation
RU2600795C1 (ru) Композиция растительного происхождения в виде мицеллярного раствора
JP2023520950A (ja) デング熱治療用生薬組成物及びその製造方法
CN111701003A (zh) 藿香正气复方在制备外用洗护用品中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22787464

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22787464

Country of ref document: EP

Kind code of ref document: A1